Breaking News
Splenectomy as Treatment for Primary Warm Autoimmune Hemolytic Anemia (wAIHA)
WHAT YOU NEED TO KNOW | EMA Recommends Suspension of Pfizer’s Sickle Cell Disease Drug Oxbryta
APLASTIC ANEMIA | Hetrombopag Achieves Significant Hematological Responses in Newly Diagnosed Patients
THALASSAEMIA WEBINAR FOR ASEAN & OCEANIA HEALTHCARE PROFESSIONALS | 21 October 2024
UNITING EXPERTS | Highlights from the 1st Nordic Red Blood Cell Meeting
ANNUAL REPORT 2023 | Unveiling TIF’s Impactful Achievements
WORLD PATIENT SAFETY DAY 2024 | Get It Right, Make It Safe!
REGULATORY APPROVAL | PiaSky Becomes the First Monthly Treatment for PNH in the EU
ACCESS TO INNOVATION | UK Greenlights Gene-Editing Therapy Casgevy for β-Thalassaemia Treatment
GLOBAL SURVEY | Understanding the Thalassaemia Community Health Literacy & Its Impact on Care
English
العربية
English
Ελληνικά
Français
Deutsch
Italiano
Menu
Home
Who we are
TIF History
Vision & Mission
Pillars of Work
Board of Directors
Staff Members
TIF Members
Collaborations
Transparency
Awards & Honours
What we do
Education
Country Work
Projects
Global Thalassaemia Review
COVID-19 Pandemic
Surveys
Haemoglobin Disorders
Thalassaemia
Sickle Cell Disease
Clinical Trial Updates
Positions & Policies
Policy Framework
Position Papers
Official Statements
Publications
TIF Publications
Scientific Literature
Additional Resources
Media Centre
News
Newsletters
Events
Videos
Contact us
Search for
Nothing Found
It seems we can’t find what you’re looking for. Perhaps searching can help.
Search for:
Back to top button
Close
Search for
